Hyundai Bioscience Co., Ltd. (048410.KQ)
KRW 11150.0
(-0.09%)
KRW 11150.0
(-0.09%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 3.73 Billion KRW | 6.2% |
| 2022 | 3.51 Billion KRW | -44.17% |
| 2021 | 6.29 Billion KRW | -64.86% |
| 2020 | 17.92 Billion KRW | 125.4% |
| 2019 | 7.95 Billion KRW | 29.54% |
| 2018 | 6.13 Billion KRW | -46.9% |
| 2017 | 11.56 Billion KRW | -20.87% |
| 2016 | 14.6 Billion KRW | 882.31% |
| 2015 | 1.48 Billion KRW | -45.56% |
| 2014 | 2.73 Billion KRW | -11.45% |
| 2013 | 3.08 Billion KRW | 248.27% |
| 2012 | -2.08 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -17 Billion KRW | -1127.89% |
| 2024 Q1 | 1.65 Billion KRW | -55.71% |
| 2023 Q4 | 3.73 Billion KRW | 44.27% |
| 2023 FY | 3.73 Billion KRW | 6.2% |
| 2023 Q1 | 2.71 Billion KRW | -22.88% |
| 2023 Q2 | 1.04 Billion KRW | -61.64% |
| 2023 Q3 | 2.58 Billion KRW | 148.85% |
| 2022 Q4 | 3.51 Billion KRW | 165.81% |
| 2022 Q1 | 6.34 Billion KRW | 0.75% |
| 2022 Q2 | 4.04 Billion KRW | -36.27% |
| 2022 Q3 | 1.32 Billion KRW | -67.29% |
| 2022 FY | 3.51 Billion KRW | -44.17% |
| 2021 Q3 | 16.22 Billion KRW | -24.35% |
| 2021 FY | 6.29 Billion KRW | -64.86% |
| 2021 Q1 | 22.87 Billion KRW | 30.33% |
| 2021 Q2 | 21.45 Billion KRW | -6.22% |
| 2021 Q4 | 6.29 Billion KRW | -61.19% |
| 2020 Q4 | 17.55 Billion KRW | 2017.16% |
| 2020 FY | 17.92 Billion KRW | 125.4% |
| 2020 Q2 | 2.09 Billion KRW | 15.23% |
| 2020 Q1 | 1.81 Billion KRW | -76.24% |
| 2020 Q3 | 829.09 Million KRW | -60.35% |
| 2019 Q3 | 11.38 Billion KRW | 107.04% |
| 2019 FY | 7.95 Billion KRW | 29.54% |
| 2019 Q4 | 7.63 Billion KRW | -32.9% |
| 2019 Q2 | 5.49 Billion KRW | -40.5% |
| 2019 Q1 | 9.23 Billion KRW | 53.7% |
| 2018 Q1 | 13.15 Billion KRW | 14.13% |
| 2018 FY | 6.13 Billion KRW | -46.9% |
| 2018 Q4 | 6.01 Billion KRW | -22.45% |
| 2018 Q3 | 7.75 Billion KRW | -44.14% |
| 2018 Q2 | 13.87 Billion KRW | 5.48% |
| 2017 Q4 | 11.52 Billion KRW | 4.34% |
| 2017 FY | 11.56 Billion KRW | -20.87% |
| 2017 Q1 | 18.6 Billion KRW | 5.83% |
| 2017 Q2 | 13.42 Billion KRW | -27.8% |
| 2017 Q3 | 11.04 Billion KRW | -17.74% |
| 2016 FY | 14.6 Billion KRW | 882.31% |
| 2016 Q2 | 6.3 Billion KRW | -8.51% |
| 2016 Q3 | 13.27 Billion KRW | 110.49% |
| 2016 Q4 | 17.57 Billion KRW | 32.42% |
| 2016 Q1 | 6.89 Billion KRW | 373.96% |
| 2015 Q3 | 3.08 Billion KRW | 34.58% |
| 2015 Q4 | 1.45 Billion KRW | -52.91% |
| 2015 Q2 | 2.29 Billion KRW | -51.11% |
| 2015 Q1 | 4.69 Billion KRW | 71.83% |
| 2015 FY | 1.48 Billion KRW | -45.56% |
| 2014 Q2 | 4.11 Billion KRW | 17.36% |
| 2014 Q3 | 3.52 Billion KRW | -14.51% |
| 2014 Q1 | 3.5 Billion KRW | 13.77% |
| 2014 Q4 | 2.73 Billion KRW | -22.42% |
| 2014 FY | 2.73 Billion KRW | -11.45% |
| 2013 FY | 3.08 Billion KRW | 248.27% |
| 2013 Q1 | 7.69 Billion KRW | 470.1% |
| 2013 Q2 | 6.03 Billion KRW | -21.62% |
| 2013 Q4 | 3.08 Billion KRW | -34.06% |
| 2013 Q3 | 4.67 Billion KRW | -22.49% |
| 2012 FY | -2.08 Billion KRW | 0.0% |
| 2012 Q4 | -2.08 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Sam Chun Dang Pharm. Co., Ltd | 13.19 Billion KRW | 71.702% |
| ST Pharm Co.,Ltd. | 141.98 Billion KRW | 97.37% |
| ABL Bio Inc. | 15.87 Billion KRW | 76.473% |
| Cellid, Co., Ltd. | -1.38 Billion KRW | 369.466% |